Characterizing vancomycin-resistant Enterococcus strains with various mechanisms of daptomycin resistance developed in an In Vitro pharmacokinetic/pharmacodynamic model

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 10, 2011, Pages 4748-4754

  Steed, Molly E ^a   Vidaillac, Celine ^a   Rose, Warren E ^d   Winterfield, Patricia ^a   Kaatz, Glenn W ^b,c   Rybak, Michael J ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME; DAPTOMYCIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL CELL WALL; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL STRAIN; CELL MEMBRANE; CELL MEMBRANE DEPOLARIZATION; DOSE RESPONSE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MORPHOLOGICAL TRAIT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PULSED FIELD GEL ELECTROPHORESIS; STAPHYLOCOCCUS AUREUS; SURFACE PROPERTY; TRANSMISSION ELECTRON MICROSCOPY; VANCOMYCIN RESISTANT ENTEROCOCCUS;

AMINOACYLTRANSFERASES; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CELL MEMBRANE; CELL WALL; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS; MEMBRANE POTENTIALS; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 80052848877     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00084-11     Document Type: Article

References (38)

1. Arias, C. A., et al. 2010. Whole-genome analysis of daptomycin- susceptible Enterococcus faecalis and its daptomycin-resistant derivative that arose during therapy, poster 245. Infect. Dis. Soc. Am. 48th Annu. Meet., Vancouver, BC, Canada, 21 to 24 October 2010.
2. Arias, C. A., et al. 2007. Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster. Clin. Infect. Dis. 45:1343-1346.
3. Benvenuto, M., D. P. Benziger, S. Yankelev, and G. Vigliani. 2006. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob. Agents Chemother. 50:3245-3249.
4. Boucher, H. W., and G. Sakoulas. 2007. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin. Infect. Dis. 45:601-608.
5. Bourgogne, A., D. Garcia, J. P. Quinn, B. E. Murray, and C. A. Arias. 2009. Transcriptome analysis of daptomycin-resistant Enterococcus faecalis, poster C1-614. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA, 12 to 15 September 2009.
6. Camargo, I. L., H. M. Neoh, L. Cui, and K. Hiramatsu. 2008. Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype. Antimicrob. Agents Chemother. 52:4289-4299.
7. Cha, R., R. G. Grucz, Jr., and M. J. Rybak. 2003. Daptomycin dose-effect relationship against resistant gram-positive organisms. Antimicrob. Agents Chemother. 47:1598-1603.
8. Clinical and Laboratory Standards Institute. 2008. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 8th ed. CLSI document M7-A8. CLSI, Wayne, PA.
9. Cotroneo, N., R. Harris, N. Perlmutter, T. Beveridge, and J. A. Silverman. 2008. Daptomycin exerts bactericidal activity without lysis of Staphylococcus aureus. Antimicrob. Agents Chemother. 52:2223-2225.
10. Cui, L., et al. 2003. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J. Clin. Microbiol. 41:5-14.
11. Cui, L., E. Tominaga, H. M. Neoh, and K. Hiramatsu. 2006. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50:1079-1082.
12. Donabedian, S., J. W. Chow, D. M. Shlaes, M. Green, and M. J. Zervos. 1995. DNA hybridization and contour-clamped homogeneous electric field electrophoresis for identification of enterococci to the species level. J. Clin. Microbiol. 33:141-145.
13. Dufour, M., et al. 2007. Characterization of monolaurin resistance in Enterococcus faecalis. Appl. Environ. Microbiol. 73:5507-5515.
14. Ernst, C. M., et al. 2009. The bacterial defensin resistance protein MprF consists of separable domains for lipid lysinylation and antimicrobial peptide repulsion. PLoS Pathog. 5:e1000660.
15. Fabretti, F., et al. 2006. Alanine esters of enterococcal lipoteichoic acid play a role in biofilm formation and resistance to antimicrobial peptides. Infect. Immun. 74:4164-4171.
16. Fowler, V. G., Jr, et al. 2006. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355:653-665.
17. Friedman, L., J. D. Alder, and J. A. Silverman. 2006. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob. Agents Chemother. 50:2137-2145.
18. Gqada, Z., et al. 2008. Clinical rationale for treatment of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin. J. Clin. Microbiol. 46:2471-2472.
19. Hobbs, J. K., K. Miller, A. J. O'Neill, and I. Chopra. 2008. Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus. J. Antimicrob. Chemother. 62:1003-1008.
20. Jones, T., et al. 2008. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob. Agents Chemother. 52:269-278.
21. Julian, K., et al. 2007. Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis. Antimicrob. Agents Chemother. 51:3445-3448.
22. Kaatz, G. W., T. S. Lundstrom, and S. M. Seo. 2006. Mechanisms of daptomycin resistance in Staphylococcus aureus. Int. J. Antimicrob. Agents 28: 280-287.
23. Khan, S. A., K. Sung, S. Layton, and M. S. Nawaz. 2008. Heteroresistance to vancomycin and novel point mutations in Tn1546 of Enterococcus faecium ATCC 51559. Int. J. Antimicrob. Agents 31:27-36.
24. Kraus, D., et al. 2008. The GraRS regulatory system controls Staphylococcus aureus susceptibility to antimicrobial host defenses. BMC Microbiol. 8:85.
25. LaPlante, K. L., M. J. Rybak, K. D. Leuthner, and J. N. Chin. 2006. Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic model. Antimicrob. Agents Chemother. 50:1298-1303.
26. Lewis, J. S., II, et al. 2005. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob. Agents Chemother. 49:1664-1665.
27. McGrath, D., et al. 2010. Resistance to daptomycin in vancomycin-resistant Enterococcus faecalis is associated with alterations of cell membrane (CM) potential and surface charge, poster C1-078. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., Boston, MA, 12 to 15 September 2010.
28. McGrath, D., et al. 2010. Transmission electron microscopy analysis of daptomycin- susceptible Enterococcus faecalis and its daptomycin-resistant derivative that arose during therapy, poster C1-079. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., Boston, MA, 12 to 15 September 2010.
29. Mishra, N. N., et al. 2009. Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53:2312-2318.
30. Montero, C. I., F. Stock, and P. R. Murray. 2008. Mechanisms of resistance to daptomycin in Enterococcus faecium. Antimicrob. Agents Chemother. 52:1167-1170.
31. Munoz-Price, L. S., K. Lolans, and J. P. Quinn. 2005. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection. Clin. Infect. Dis. 41:565-566.
32. Roy, H., and M. Ibba. 2009. Broad range amino acid specificity of RNAdependent lipid remodeling by multiple peptide resistance factors. J. Biol. Chem. 284:29677-29683.
33. Sakoulas, G., et al. 2008. Evaluation of endocarditis caused by methicillinsusceptible Staphylococcus aureus developing nonsusceptibility to daptomycin. J. Clin. Microbiol. 46:220-224.
34. Sharma, M., K. Riederer, P. Chase, and R. Khatib. 2008. High rate of decreasing daptomycin susceptibility during the treatment of persistent Staphylococcus aureus bacteremia. Eur. J. Clin. Microbiol. Infect. Dis. 27: 433-437.
35. Silverman, J. A., N. G. Perlmutter, and H. M. Shapiro. 2003. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 47:2538-2544.
36. Tenover, F. C., et al. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.
37. Yang, S. J., et al. 2009. Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J. Infect. Dis. 200:1916-1920.
38. Yang, S. J., et al. 2009. Regulation of mprF in daptomycin-nonsusceptible Staphylococcus aureus strains. Antimicrob. Agents Chemother. 53:2636-2637.